Stockreport

IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights

IN8bio, Inc.  (INAB) 
PDF Presented new preclinical data on INB-619, a novel gamma-delta (?d) T cell engager (TCE), demonstrating equivalent potency comparable to FDA-approved commercial products [Read more]